Day One Biopharmaceuticals Inc [NASDAQ: DAWN] price plunged by -15.70 percent to reach at -$1.08.
A sum of 9261318 shares traded at recent session while its average daily volume was at 1.48M shares. Day One Biopharmaceuticals Inc shares reached a high of $6.09 and dropped to a low of $5.635 until finishing in the latest session at $5.8.
The one-year DAWN stock forecast points to a potential upside of 75.58. The average equity rating for DAWN stock is currently 1.22, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Day One Biopharmaceuticals Inc [DAWN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DAWN shares is $23.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DAWN stock is a recommendation set at 1.22. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Needham have made an estimate for Day One Biopharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 09, 2024. While these analysts kept the previous recommendation, BofA Securities raised their target price from $11 to $24. The new note on the price target was released on August 01, 2024, representing the official price target for Day One Biopharmaceuticals Inc stock. Previously, the target price had yet another raise from $30 to $33, while Needham kept a Buy rating on DAWN stock. On April 25, 2023, analysts decreased their price target for DAWN shares from 34 to 9.
The Price to Book ratio for the last quarter was 1.29, with the Price to Cash per share for the same quarter was set at 4.47.
DAWN Stock Performance Analysis:
Day One Biopharmaceuticals Inc [DAWN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.57. With this latest performance, DAWN shares dropped by -12.25% in over the last four-week period, additionally sinking by -52.26% over the last 6 months – not to mention a drop of -54.22% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DAWN stock in for the last two-week period is set at 32.91, with the RSI for the last a single of trading hit 0.41, and the three-weeks RSI is set at 0.36 for Day One Biopharmaceuticals Inc [DAWN]. The present Moving Average for the last 50 days of trading for this stock 6.70, while it was recorded at 6.56 for the last single week of trading, and 9.85 for the last 200 days.
Insight into Day One Biopharmaceuticals Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Day One Biopharmaceuticals Inc [DAWN] shares currently have an operating margin of -59.55% and a Gross Margin at 94.02%. Day One Biopharmaceuticals Inc’s Net Margin is presently recorded at -50.63%.
Day One Biopharmaceuticals Inc (DAWN) Capital Structure & Debt Analysis
According to recent financial data for Day One Biopharmaceuticals Inc. ( DAWN), the Return on Equity (ROE) stands at -24.75%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -20.66%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Day One Biopharmaceuticals Inc’s Return on Invested Capital (ROIC) is -20.49%, showcasing its effectiveness in deploying capital for earnings.
Day One Biopharmaceuticals Inc (DAWN) Efficiency & Liquidity Metrics
Based on Day One Biopharmaceuticals Inc’s (DAWN) latest financial statements, the Debt-to-Equity Ratio is 0.01%, indicating its reliance on debt financing relative to shareholder equity.
Day One Biopharmaceuticals Inc (DAWN) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Day One Biopharmaceuticals Inc. (DAWN) effectively leverages its workforce, generating an average of -$524861.88 per employee. The company’s liquidity position is robust, with a Current Ratio of 9.65% and a Quick Ratio of 9.53%, indicating strong ability to cover short-term liabilities.
Day One Biopharmaceuticals Inc [DAWN] Institutonal Ownership Details
There are presently around $94.89%, or 114.38%% of DAWN stock, in the hands of institutional investors. The top three institutional holders of DAWN stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 7.87 million shares, which is approximately 9.0354%. ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC, holding 6.43 million shares of the stock with an approximate value of $$88.61 million in DAWN stocks shares; and ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC, currently with $$63.71 million in DAWN stock with ownership which is approximately 5.3067%.
